The AJMC® Dermatology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the skin, hair, and nails.
March 24th 2023
The lower number needed to treat suggests that ruxolitinib cream may be more effective for patients with atopic dermatitis (AD), according to a poster presented at AMCP 2023.
Lower Risk of Cardiovascular, Metabolic Outcomes Associated With Rituximab for Pemphigus Treatment
December 8th 2022Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line corticosteroid-sparing agents azathioprine and mycophenolate mofetil.
Read More
Low Diversity Shown Among Medical Students Pursuing Dermatology
December 2nd 2022Female allopathic medical students pursuing careers in dermatology were less likely than those pursuing other specialties to be from racial and ethnic groups underrepresented in medicine or be a sexual minority, with a lack of interest in underserved care and public health shown overall.
Read More
Use of PRO Measures Lacking in Acne Vulgaris and Rosacea Clinical Trials, Study Finds
December 2nd 2022Patient-reported outcome (PRO) measures were included in approximately one-half of acne vulgaris and rosacea randomized controlled trials, despite their utility in capturing the patient perspective.
Read More
CKD Severity, Proteinuria Associated With Risk of Prurigo Nodularis
November 22nd 2022Korean patients who had more advanced chronic kidney disease (CKD), defined by estimated glomerular filtration rate of 29 or less vs 90 or more, and presence of proteinuria were associated with greater risk of prurigo nodularis.
Read More
Diagnostic Criteria for Hidradenitis Suppurativa May Overlook Pediatric Patients
November 16th 2022More than a third (42.8%) of pediatric patients with hidradenitis suppurativa did not meet all major diagnostic criteria at the time of diagnosis, particularly due to failure to fulfill the recurrence interval criterion (2 or more lesions within 6 months).
Read More
Social Impact of Hidradenitis Suppurativa Associated With Worse QOL, Mental Health Burden
November 11th 2022Patients with hidradenitis suppurativa who reported feelings of stigmatization due to their condition had worse quality of life and higher levels of depression and social anxiety vs those not reporting feelings of stigmatization.
Read More
Hidradenitis Suppurativa ED Readmission Linked to Opioid Prescribing, Medicaid Insurance
November 1st 2022Emergency department (ED) readmission was more common than dermatology follow-up among patients with hidradenitis suppurativa (HS) within 30 and 180 days of initially presenting to the ED, with patients with Medicaid coverage and those who had an opioid prescribed were more likely to return.
Read More
Exploring Strategies for Timely Diagnosis, Comprehensive Care in Hidradenitis Suppurativa
October 18th 2022Researchers reviewed clinical features of hidradenitis suppurativa and provided strategies to promote earlier identification, differentiation from common mimickers, and timely referrals for multidisciplinary management.
Read More
Assessing Surgical Complications in Management of Hidradenitis Suppurativa
October 10th 2022Approximately 1 in 10 patients with hidradenitis suppurativa (HS) experienced complications related to surgery for HS management, in which extensive resection, using skin flaps or skin grafts as a closure method, was associated with a higher incidence of complications.
Read More
Shared Decision-Making Linked With Improved Treatment Satisfaction in Alopecia Areata
September 8th 2022Patients with alopecia areata were less likely to report decisional regret regarding treatment when dermatologists incorporated shared decision-making, with prescription of Janus kinase (JAK) inhibitors associated with the lowest decisional regret.
Read More
Real-world Data Confirm Early Efficacy of Anti-IL-17A Inhibitors for Psoriasis
August 17th 2022Treatment with anti-interleukin (IL)-17A inhibitors for psoriasis consistently improved outcomes across primary and secondary endpoints compared with all other approved biologics, and researchers also found differences between anti-IL-17A inhibitors.
Read More
Advocate Speaks on Prior Authorization, Insurance-Related Barriers for HS Treatment
August 13th 2022Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), discussed step edits and other barriers to treatment caused by insurance requirements in the management of HS.
Watch
Disease Burden of Alopecia Areata Greater in Lower-Income Countries
August 11th 2022Despite decreasing trends observed in the global burden of alopecia areata, low-income countries and Western Sub-Saharan Africa regions continue to exhibit rising incidence and disability-adjusted life-years rates.
Read More
Advocate Addresses Factors Physicians Should Consider in Managing Hidradenitis Suppurativa
August 5th 2022Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on the need for awareness among physicians and patients on the clinical features of HS in regard to both physical and psychosocial burdens.
Watch
Advocate Discusses Her Family's History With Hidradenitis Suppurativa
July 30th 2022The journey to a diagnosis of hidradenitis suppurativa was different for her compared with the path faced by her children, said Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with the disease.
Watch
Risk of Myocardial Infarction Greater Among Patients With Hidradenitis Suppurativa
July 25th 2022An increased risk of developing myocardial infarction was observed among patients with hidradenitis suppurativa (HS), whereas risk of cerebrovascular accident and peripheral vascular disease was comparable between those with HS and controls.
Read More
Dr Jonathan Kentley Discusses Training Algorithms to Detect Melanoma
July 16th 2022Many algorithms claiming to identify melanoma better than dermatologists are trained on retrospective datasets, which is not reflective of real-world clinical practice, said Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center.
Watch